These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 22551924)

  • 21. [From ASCO and WCLC 2005 to the clinical practice: targeted therapies].
    Pérol M
    Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S30-4. PubMed ID: 16719154
    [No Abstract]   [Full Text] [Related]  

  • 22. Personalized medicine for non-small-cell lung cancer.
    Mok TS; Zhou Q; Leung L; Loong HH
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
    Gridelli C
    Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
    [No Abstract]   [Full Text] [Related]  

  • 24. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
    Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K
    J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer.
    Reckamp KL
    Cancer Lett; 2012 Aug; 321(2):101-9. PubMed ID: 22306704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer.
    Socinski MA
    Cancer Treat Rev; 2011 Dec; 37(8):611-7. PubMed ID: 21641723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
    Subramanian J; Morgensztern D; Govindan R
    Clin Lung Cancer; 2010 Sep; 11(5):311-9. PubMed ID: 20837456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New biological treatments for lung cancer].
    Zalcman G; Richard N; Bergot E
    Rev Pneumol Clin; 2007 Feb; 63(1):20-8. PubMed ID: 17457280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted therapy and new anticancer drugs in advanced disease.
    Silva S; Danson S
    Thorac Surg Clin; 2013 Aug; 23(3):411-9. PubMed ID: 23931023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current overview of angiogenesis inhibitors.
    Ellis LM
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
    [No Abstract]   [Full Text] [Related]  

  • 31. Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer.
    Bertino EM; Otterson GA
    Lung Cancer; 2010 Dec; 70(3):233-46. PubMed ID: 20888062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.
    Wijesinghe P; Bollig-Fischer A
    Adv Exp Med Biol; 2016; 890():1-23. PubMed ID: 26703796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beyond the vascular endothelial growth factor axis: update on role of imaging in nonantiangiogenic molecular targeted therapies in oncology.
    Howard SA; Rosenthal MH; Jagannathan JP; Krajewski KM; Shinagare AB; Ramaiya NH; Tirumani SH
    AJR Am J Roentgenol; 2015 May; 204(5):919-32. PubMed ID: 25905926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Targeted therapies for lung cancer].
    Tamura K
    Rinsho Ketsueki; 2008 Aug; 49(8):616-21. PubMed ID: 18800610
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?
    Lorusso PM; Boerner SA; Hunsberger S
    J Clin Oncol; 2011 Aug; 29(22):2952-5. PubMed ID: 21709201
    [No Abstract]   [Full Text] [Related]  

  • 36. Journey of the ALK-inhibitor CH5424802 to phase II clinical trial.
    Latif M; Saeed A; Kim SH
    Arch Pharm Res; 2013 Sep; 36(9):1051-4. PubMed ID: 23700294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted Therapies for Non-Small Cell Lung Cancer: An Update on Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Inhibitors.
    Kreamer K; Riordan D
    Clin J Oncol Nurs; 2015 Dec; 19(6):734-42. PubMed ID: 26583637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unanswered questions: monoclonal antibodies in the treatment of advanced non-small-cell lung cancer.
    Gridelli C; Rossi A
    Oncology (Williston Park); 2010 Nov; 24(13):1216-23. PubMed ID: 21192561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.
    Cottini F; Lautenschlaeger T
    Cancer J; 2013; 19(3):263-71. PubMed ID: 23708073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lung adenocarcinoma: lessons in translation from bench to bedside.
    Sangodkar J; Katz S; Melville H; Narla G
    Mt Sinai J Med; 2010; 77(6):597-605. PubMed ID: 21105123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.